E-resources
PDF-
Xie, John; Jang, Albert; Vegel, Andrew; Hajja, Yasmin; Mouawad, Yara; Baghian, Ali; Berbari, Bachir; Schmid, Janet L.; Socola, Francisco; Safah, Hana; Saba, Nakhle S.
Leukemia research reports, 01/2021, Volume: 15Journal Article
“Accelerated” chronic lymphocytic leukemia/small lymphocytic lymphoma (A-CLL) is a rare histological variant of CLL/SLL, which tends to exhibit an aggressive clinical behavior compared to CLL. Due to the rarity of A-CLL (<1% of all cases), the optimal management remains ill-defined. We report two cases of A-CLL from our institution, in which both relapsed following initial chemoimmunotherapy regimens. Both patients were treated with single agent ibrutinib, a Bruton's tyrosine kinase inhibitor (BTKi), and achieved rapid, deep and durable responses. With the absence of clear guidance on A-CLL treatment, BTKi agents should be considered in the frontline treatment of A-CLL.
